|
ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). |
|
|
Leadership - Atropos; Certis Oncology Solutions |
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions |
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; GlaxoSmithKline; Immune Design; Janssen; Lilly; Loxo; Nanocell Therapy; Novartis; Plexxikon |
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma |
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy- 62/671,625 |
|
|
|
Consulting or Advisory Role - Daiichi Sankyo; Five Prime Therapeutics; Lilly; Loxo |
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Daiichi Sankyo; Immune Design; Janssen; Lilly; Novartis |
|
|
Honoraria - Amgen; Eisai; Lilly; Merck Sharp & Dome |
Consulting or Advisory Role - Lilly; Merck Sharp & Dome |
Research Funding - Efficient Pharma Management Corp.; Eisai; Lilly; Ono Pharmaceutical; TLC PharmaChem |
Travel, Accommodations, Expenses - Merck Sharp & Dome; Ono Pharmaceutical; Roche |
|
|
Consulting or Advisory Role - Adaptimmune (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Intellisphere (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Plexxikon (Inst); SERVIER (Inst); Transgene (Inst) |
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst) |
|
Albiruni Ryan Abdul Razak |
Honoraria - Boehringer Ingelheim |
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Merck |
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics; Lilly; MedImmune; Merck; Novartis; Pfizer; Roche/Genentech |
|
|
Honoraria - Lilly; PharmaMar |
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar |
Speakers' Bureau - PharmaMar |
Research Funding - Eisai (Inst); GlaxoSmithKline; Lilly (Inst); Novartis (Inst); PharmaMar |
Expert Testimony - Novartis; PharmaMar |
Travel, Accommodations, Expenses - Pfizer; PharmaMar |
|
|
Honoraria - AstraZeneca/MedImmune; CytomX Therapeutics; Merck |
Consulting or Advisory Role - Array BioPharma (Inst) |
Research Funding - Abbvie (Inst); Archer (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst) |
|
|
Honoraria - Eisai; Lilly; Novartis; Taiho Pharmaceutical; Takara Bio |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Lilly; Novartis; Pfizer; PharmaMar |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; Lilly; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Bayer; Chugai Pharma; Lilly; Meiji Seika Kaisha; Merck Serono; Nippon Kayaku; Novartis; Pfizer; Roche; Taiho Pharmaceutical |
|
|
|
Consulting or Advisory Role - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - ImClone LCC, wholly owned subsidiary of Eli Lilly and Company; Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
|
|
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma |
Research Funding - GlaxoSmithKline (Inst) |
Travel, Accommodations, Expenses - PharmaMar |